Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | STAT6 | P42226 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15111460 | 0.83 | CYP2C19 (0.32) | CYP2C19ALDH1A1FFAR3 | |
| SCHEMBL19315868 | 0.83 | SERPINA6 (0.32) | CYP2C19SHBGMAPK1THPOGMNN | |
| SCHEMBL1834809 | 0.83 | CYP1A2 (0.36) | CYP2C19ALDH1A1FFAR3MAPK1TP53 | |
| SCHEMBL30716833 | 0.81 | CYP2C19 (0.42) | CYP2C19ALDH1A1FFAR3 | |
| SCHEMBL245571 | 0.81 | — | — | |
| SCHEMBL578419 | 0.81 | JAK2 (0.31) | SHBGSMN1; SMN2 | |
| SCHEMBL16875355 | 0.81 | CYP2C19 (0.42) | CYP2C19ALDH1A1LMNAMTORPMP22 | |
| SCHEMBL10501307 | 0.81 | ALDH1A1 (0.35) | CYP2C19ALDH1A1FFAR3SMN1; SMN2 | |
| SCHEMBL9680414 | 0.81 | CYP2C19 (0.33) | CYP2C19ALDH1A1FFAR3 | |
| SCHEMBL16875354 | 0.81 | CYP2C19 (0.42) | CYP2C19ALDH1A1LMNAMTORPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-110028491-B | Fibroblast growth factor receptor inhibitors | 缆图药品公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3243385-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3243385-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2677869-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2802330-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013106535-A9 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-8796258-B2 | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2677869-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2013106535-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2006038112-A1 | USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABBOTT LABORATORIES | 2006-02-02 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005074603-A2 | AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-08-18 | — | — | WO | disclosed |
| EP-1549651-A1 | KINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004011465-A1 | KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040019210-A1 | Kinase inhibitors | CHIVIKAS CONNOLLY CLEO J (US) | 2004-01-29 | — | — | US | disclosed |
| US-5175319-A | Antiprotozoa agent, useful for treating malaria, theileriosis, coccidiosis and prophylaxix | BURROUGHS WELLCOME CO. (US) | 1992-12-29 | — | — | US | disclosed |
| US-5053432-A | Antiprotozoa agents; treatment of malaria | BURROUGHS WELLCOME CO. (US) | 1991-10-01 | — | — | US | disclosed |
| EP-0123238-B1 | NAPHTHOQUINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025383-A1 | Aminobenzoxazoles as therapeutic agents | ABL1, MAP3K19, MAP3K20 | CYP2C19 351/4885ALDH1A1 1952/4885FFAR3 4184/4885 |
| US-20040019210-A1 | Kinase inhibitors | CDK2, CDK1, CDK4 | CYP2C19 1132/4885ALDH1A1 1779/4885FFAR3 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.